Research Paper on Evidence from a Medical Record Review in France on Real-World Treatment Patterns, Results, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma

Description

Title: Evidence from a Medical Record Review in France on Real-World Treatment Patterns, Results, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma

Abstract: Background. There is a lack of information about treatment patterns and outcomes in relapsed/refractory multiple myeloma (RRMM), particularly by cytogenetic risk, from real-world practices in Europe. Methods. 200 patients with RRMM were the subject of a retrospective medical record review in France. Patients’ second- and third-line treatments, progression-free survival (PFS), overall survival (OS), and healthcare use were evaluated starting with their first relapse. Results. Patients with 55 high risk factors and 113 standard risk factors were found. After relapse, 192 patients overall (96%) received second-line therapy. In the second line, lenalidomide-based regimens were the most prevalent (>50%). About twice as many high risk patients ended up in hospitals as standard risk patients did. According to Kaplan-Meier estimation, the second-line PFS median (95% CI) was 21.4 (17.5, 25.0) months (by high versus standard risk: 10.6 [6.4, 17.0] versus 28.7 [22.1, 37.3] months). 47.4% of second-line recipients were dead at the time of data collection. Second-line OS median duration was 59.4 (38.8, NE) months (by high versus standard risk: 36.5 [17.4, 50.6] versus 73.6 [66.5, NE] months). Conclusions. It was found that cytogenetic risk was significant for prognosis in RRMM, with high (versus standard) risk patients having significantly shorter PFS and OS. Frequent hospitalizations suggested that RRMM could be expensive, especially for high risk patients. These results might influence how RRMM treatments are evaluated economically.

Paper Quality: SCOPUS / Web of Science Level Research Paper

Subject: Medicine

Sub Category: Hematology

Writer Experience: 20+ Years

Plagiarism Report: Turnitin Plagiarism Report will be less than 10%

Restriction: Only one author may purchase a single paper. The paper will then indicate that it is out of stock.

What will I get after the purchase?

A turnitin plagiarism report of less than 10% in a pdf file and a full research paper in a word document.

In case you have any questions related to this research paper, please feel free to call/ WhatsApp on +919726999915